Global Home Global Home
MÉXICO
CIENCIAS INNOVADORAS, TECNOLOGIAS DE VANGUARDIA

Publicaciones archivadas
....................................................................................................................................................................................

Estas publicaciones acerca de Oculus Incorporated están ordenadas por fecha, desde la más reciente a la más antigua. Necesitará Adobe® Reader®, un programa gratuito, para ver los documentos en PDF.

2008

March 28, 2008
Oculus Innovative Sciences, Inc., Announces $13.9 Million Securities Offering

March 27, 2008
Oculus Innovative Sciences Receives Chinese SFDA Regulatory Approval of Microcyn® Technology

March 17, 2008
Oculus Innovative Sciences Announces Positive Results From Three Abstracts Evaluating the Use of Microcyn® Technology in Diabetic Foot Ulcers

March 14, 2008
Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

March 12, 2008
Oculus Innovative Sciences Announces Acceptance of Three Abstracts on the use of Microcyn® Technology in Diabetic Foot Ulcers by DFCon 08

March 11, 2008
Oculus Innovative Sciences to Announce Additional Phase II Data and Data from Two Recent International Studies at DFCon 08

February 27, 2008
Oculus Innovative Sciences Schedules Conference Call Today to Discuss Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 27, 2008
Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

February 14, 2008
Oculus Innovative Sciences to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference

February 7, 2008
Oculus Innovative Sciences Announces Fiscal Third Quarter 2008 Quarterly Results and Clinical Update

February 5, 2008
Oculus Schedules Fiscal Third Quarter 2008 Financial Results Release and Conference Call

January 29, 2008
Oculus Innovative Sciences Announces Agreement with Animal Health International for North American Distribution of Microcyn®-Based Vetericyn™ Wound Spray

January 24, 2008
Oculus Innovative Sciences Awarded Damages by Federal Court in Intellectual Property Rights Litigation

January 22, 2008
Top-Line Data from Oculus Innovative Sciences' Phase II Trial to Be Presented at DFCon 08 (Diabetic Foot Global Conference) on March 14, 2008

January 17, 2008
Oculus Innovative Sciences, Inc. Appoints Gregg Alton to its Board of Directors

January 3, 2008
Oculus Innovative Sciences Completes Patient Treatment and Follow-up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers

 

2007

December 18, 2007
Oculus Innovative Sciences Announces Completion of Two Randomized Controlled Clinical Trials of Microcyn® Technology in China

December 5, 2007
Oculus Innovative Sciences Completes Enrollment of Phase II Trial of Microcyn® Technology in Treatment of Mildly Infected Diabetic Foot Ulcers

November 19, 2007
Oculus Innovative Sciences Wins Federal Court Ruling in Intellectual Property Rights Litigation

November 12, 2007
Oculus Innovative Sciences Announces Fiscal Second Quarter 2008 Quarterly Results and Clinical Update

November 8, 2007
Oculus Innovative Sciences Schedules Fiscal Second Quarter 2008 Financial Results Release and Conference Call

November 1, 2007
Oculus Innovative Sciences to Present at SMH Capital Markets Investor Growth Conference

October 30, 2007
Oculus Innovative Sciences to Present at Acumen BioFin 9th Annual Healthcare Conference

October 3, 2007
Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference

September 17, 2007
Oculus Innovative Sciences Microcyn Technology Data to be Presented by Researchers at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

September 17, 2007
Oculus Innovative Sciences Provides Update of Phase II Study for Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

September 14, 2007
Oculus Innovative Sciences to Conduct Conference Call Update on Phase II Study of Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers

September 6, 2007
Oculus Innovative Sciences to Present at First Albany Capital Regenerative Technologies Conference

August 29, 2007
Oculus Innovative Sciences to Present at Roth Capital Partners 2007 New York Conference

August 9, 2007
Oculus Innovative Sciences Announces Fiscal First Quarter 2008 Financial Results

August 8, 2007
Oculus Innovative Sciences Announces $10.1 Million Private Placement of Common Stock

August 3, 2007
Oculus Innovative Sciences Schedules Fiscal First Quarter 2008 Financial Results Release and Conference Call

June 26, 2007
Oculus Innovative Sciences Announces Results From Anti-Inflammatory Study Using Microcyn® Technology

June 18, 2007
Oculus Innovative Sciences Appoints Vice President of Regulatory Affairs and Quality

June 13, 2007
Drug Enhancement Company of America Licenses Oculus' Microcyn® Technology for Use in First Responder ''Pen-Like'' Applicator

June 7, 2007
Oculus Announces Fiscal Fourth Quarter and Full Year 2007 Financial Results

June 6, 2007
Oculus Schedules Fiscal Fourth Quarter and Full Year 2007 Financial Results Release and Conference Call

May 21, 2007
Oculus Initiates Patient Enrollment in Phase II Study of Microcyn® Technology for Treatment of Mild Diabetic Foot Infections

May 14, 2007
Oculus Innovative Sciences Microcyn® Technology Presented in Poster at European Wound Management Association Conference

May 9, 2007
Oculus Innovative Sciences to Present at Rodman & Renshaw Global Healthcare Conference

April 26, 2007
China Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute Oculus' Microcyn®-Based Wound Care Solution in China

April 25, 2007
Oculus Innovative Sciences, Inc. Appoints Jay E. Birnbaum to Its Board of Directors

March 29, 2007
Oculus Announces Initial Sites for Phase II Clinical Trial of Microcyn® Technology in Treatment of Mild Diabetic Foot Infections

March 13, 2007
Oculus' Dermacyn® Wound Care Subject of 33-Patient Study Published in International Journal of Lower Extremity Wounds

February 22, 2007
Oculus Innovative Sciences Announces Fiscal Third Quarter 2007 Results

January 24, 2007
Oculus Innovative Sciences, Inc. Announces Initial Public Offering

 

2006

July 5, 2006
Oculus Innovative Sciences, Inc. Files Registration Statement with the SEC for Proposed Initial Public Offering

 

2004

1 de noviembre de 2004
Oculus Receives Regulatory Approval To Market Dermacyn™ Wound Care in Canada. (En inglés).

24 de julio de 2004
Oculus Lanunches First U.S. Product Formulated with Microcyn Technology. (En inglés).
(PDF: 92 KB)

14 de mayo de 2004
Oculus Files 510(K) with FDA for Approval of Microcyn as Wound Care Dressing. (En inglés).
(PDF: 92 KB)

14 de mayo de 2004
Oculus Files Application with U.S. EPA for Approval of Microcyn as a Hospital-Grade Disinfectant. (En inglés).
(PDF: 90 KB)

1 de mayo de 2004
Oculus Closes Series "A" Round of Financing for $8 Million. (En inglés).
(PDF: 93 KB)

16 de abril de 2004
Mexican Ministry of Health Approves Microcyn Technology for Use in Veterinarian Market. (En inglés).
(PDF: 93 KB)

31 de marzo de 2004
Oculus Microcyn60 Disinfectant (OMD) Technology Receives CE Mark Approval as Disinfectant for Non-Critical Medical Devices in Europe. (En inglés).
(PDF: 94 KB)

9 de enero de 2004
Oculus Applies for CE Mark Approval for California Manufacturing Facility. (En inglés).. (Corregida el 11 de enero de 2004)
(PDF: 92 KB)

9 de enero de 2004
Microcyn Receives Approval as a Sterilant from Mexican Ministry of Health. (En inglés).
(PDF: 90 KB)

2003

19 de diciembre de 2003
Oculus Completes Incorporation of Legal Entity in the Netherlands and Prepares for Opening of European Manufacturing Facility for Microcyn Technology. (En inglés).
(PDF: 92 KB)

11 de noviembre de 2003
Oculus Innovative Sciences Launches Microcyn in Mexico. (En inglés).
(PDF: 94 KB)

1 de octubre de 2003
Oculus Files for Pre-Investigational Meeting with FDA to Review Microcyn60 Antiseptic Technology. (En inglés).
(PDF: 90 KB)

18 de septiembre de 2003
MicroMed Consulting Group Announces Strategic Partnership with Roberts Consulting & Engineering. (En inglés).
(PDF: 92 KB)

9 de septiembre de 2003
Oculus Innovative Sciences Opens European Office as Company Seeks CE Mark Approval of Microcyn60 Disinfectant and Antiseptic. (En inglés).
(PDF: 91 KB)

9 de septiembre de 2003
Jim Schutz Joins Oculus Innovative Sciences as General Counsel and Corporate Secretary. (En inglés).
(PDF: 90 KB)

2 de septiembre de 2003
Dr. Andres Gutierrez of Mexican Ministry of Health Joins Oculus Advisory Board. (En inglés).
(PDF: 91 KB)

28 de agosto de 2003
Mexico's Ministry of Health to Initiate Limited Clinical Trials of Oculus's "L3" Oncology Compound in Treatment of Cervical Cancer. (En inglés).
(PDF: 92 KB)

14 de agosto de 2003
Oculus Innovative Sciences Announces Appointment of Executive Vice President and Director of Business Development. (En inglés).
(PDF: 93 KB)

31 de julio de 03
Microcyn60 Disinfectant from Oculus Innovative Sciences Receives Mexican Ministry of Health Approval. (En inglés).
(PDF: 92 KB)

NOTA: Los productos/las indicaciones para el control de heridas no están aprobados por la FDA (Administración de Alimentos y Medicamentos) de los EE.UU.